Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)

    Summary
    EudraCT number
    2016-000933-37
    Trial protocol
    HU   DE   LV   PT   SE   ES   CZ   BE   NL   SK   BG   IT  
    Global end of trial date
    06 Jun 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    15 Jun 2024
    First version publication date
    15 Jun 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    M15-925
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03086343
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    AbbVie Deutschland GmbH & Co. KG
    Sponsor organisation address
    AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6 4UB
    Public contact
    Global Medical Services, AbbVie, 001 8006339110, abbvieclinicaltrials@abbvie.com
    Scientific contact
    Global Medical Services, AbbVie, 001 8006339110, abbvieclinicaltrials@abbvie.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    06 Jun 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    06 Jun 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in biologic disease-modifying antirheumatic drug (bDMARD)-inadequate response or bDMARD-intolerant participants with moderately to severely active RA. The study objective of Period 2 is to evaluate the long term safety, tolerability, and efficacy of upadacitinib 15 mg QD in participants with RA who had completed Period 1.
    Protection of trial subjects
    Subject and/or legal guardian read and understood the information provided about the study and gave written permission.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    09 May 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Argentina: 76
    Country: Number of subjects enrolled
    Australia: 5
    Country: Number of subjects enrolled
    Belgium: 1
    Country: Number of subjects enrolled
    Brazil: 59
    Country: Number of subjects enrolled
    Bulgaria: 47
    Country: Number of subjects enrolled
    Canada: 2
    Country: Number of subjects enrolled
    Czechia: 24
    Country: Number of subjects enrolled
    Germany: 27
    Country: Number of subjects enrolled
    Greece: 4
    Country: Number of subjects enrolled
    Hungary: 20
    Country: Number of subjects enrolled
    Israel: 13
    Country: Number of subjects enrolled
    Italy: 2
    Country: Number of subjects enrolled
    Korea, Republic of: 8
    Country: Number of subjects enrolled
    Latvia: 4
    Country: Number of subjects enrolled
    Mexico: 62
    Country: Number of subjects enrolled
    Netherlands: 9
    Country: Number of subjects enrolled
    New Zealand: 2
    Country: Number of subjects enrolled
    Poland: 42
    Country: Number of subjects enrolled
    Portugal: 23
    Country: Number of subjects enrolled
    Puerto Rico: 8
    Country: Number of subjects enrolled
    Romania: 2
    Country: Number of subjects enrolled
    Russian Federation: 24
    Country: Number of subjects enrolled
    Spain: 16
    Country: Number of subjects enrolled
    Sweden: 1
    Country: Number of subjects enrolled
    Switzerland: 5
    Country: Number of subjects enrolled
    Türkiye: 3
    Country: Number of subjects enrolled
    United Kingdom: 3
    Country: Number of subjects enrolled
    United States: 165
    Worldwide total number of subjects
    657
    EEA total number of subjects
    222
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    512
    From 65 to 84 years
    143
    85 years and over
    2

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study had a 24-week, randomized, double-blind, parallel-group, active-controlled period (Period 1) and an open-label long-term extension study (Period 2). Primary Cohort: Participants enrolled under Amendment 4 or 3.01, randomized to upadacitinib 15 mg QD or abatacept IV/upadacitinib 15 mg QD.

    Pre-assignment
    Screening details
    30 mg Cohort: Participants enrolled under Amendment 3, randomized to upadacitinib 30 mg QD or abatacept IV/upadacitinib 30 mg QD. Starting with Amendment 5, all participants received open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.

    Period 1
    Period 1 title
    Period 1
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor
    Blinding implementation details
    All AbbVie personnel with direct oversight of the conduct and management of the trial (with the exception of AbbVie Drug Supply Management Team and unblinded monitors conducting study drug accountability), the Investigator, study site personnel, and the subject will remain blinded to each subject's treatment throughout the study.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Primary Cohort: Upadacitinib 15 mg QD
    Arm description
    Period 1: One 15 mg upadacitinib oral tablet taken once per day (QD) for 24 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Upadacitinib
    Investigational medicinal product code
    Other name
    ABT-494
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    One 15 mg tablet taken once per day by mouth

    Investigational medicinal product name
    Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    IV infusion: Day 1, Weeks 2, 4, 8, 12, 16, and 20

    Arm title
    Primary Cohort: Abatacept
    Arm description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20.
    Arm type
    Experimental

    Investigational medicinal product name
    Abatacept
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20.

    Investigational medicinal product name
    Placebo for upadacitinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    matching placebo taken orally QD

    Arm title
    30 mg Cohort: Upadacitinib 30 mg QD
    Arm description
    Period 1: One upadacitinib 30 mg oral tablet QD for 24 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Upadacitinib
    Investigational medicinal product code
    Other name
    ABT-494
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    One 30 mg tablet taken once per day by mouth for 24 weeks

    Investigational medicinal product name
    Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    IV infusion: Day 1, Weeks 2, 4, 8, 12, 16, and 20

    Arm title
    30 mg Cohort: Abatacept
    Arm description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20.
    Arm type
    Experimental

    Investigational medicinal product name
    Abatacept
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20

    Investigational medicinal product name
    Placebo for upadacitinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    matching placebo taken orally QD

    Number of subjects in period 1 [1]
    Primary Cohort: Upadacitinib 15 mg QD Primary Cohort: Abatacept 30 mg Cohort: Upadacitinib 30 mg QD 30 mg Cohort: Abatacept
    Started
    303
    309
    21
    23
    Completed
    278
    277
    18
    21
    Not completed
    25
    32
    3
    2
         Consent withdrawn by subject
    6
    10
    -
    -
         Adverse Event
    7
    7
    -
    1
         Lost to follow-up
    1
    3
    1
    -
         Missing
    1
    -
    -
    -
         Other, Not Specified
    10
    12
    2
    1
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: One participant who was a screen failure was randomized in error and did not receive study drug.
    Period 2
    Period 2 title
    Period 2
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Primary Cohort: Upadacitinib 15 mg QD/Upadacitinib 15 mg QD
    Arm description
    Period 1: One 15 mg upadacitinib oral tablet QD for 24 weeks. Period 2: open label upadacitinib 15 mg QD for 192 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Upadacitinib
    Investigational medicinal product code
    Other name
    ABT-494
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    One 15 mg tablet taken once per day by mouth

    Arm title
    Primary Cohort: Abatacept/Upadacitinib 15 mg QD
    Arm description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 15 mg QD for 192 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Upadacitinib
    Investigational medicinal product code
    Other name
    ABT-494
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    One 15 mg tablet taken once per day by mouth

    Arm title
    30 mg Cohort: Upadacitinib 30 mg QD/Upadacitinib 30 mg QD
    Arm description
    Period 1: One upadacitinib 30 mg oral tablet QD for 24 weeks. Period 2: open label upadacitinib 30 mg (reduced to 15 mg per Amendment 5) QD for 192 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Upadacitinib
    Investigational medicinal product code
    Other name
    ABT-494
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    One 30 mg tablet taken once per day by mouth

    Arm title
    30 mg Cohort: Abatacept/Upadacitinib 30 mg QD
    Arm description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 30 mg (reduced to 15 mg per Amendment 5) QD for 192 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Upadacitinib
    Investigational medicinal product code
    Other name
    ABT-494
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    One 30 mg tablet taken once per day by mouth

    Number of subjects in period 2 [2]
    Primary Cohort: Upadacitinib 15 mg QD/Upadacitinib 15 mg QD Primary Cohort: Abatacept/Upadacitinib 15 mg QD 30 mg Cohort: Upadacitinib 30 mg QD/Upadacitinib 30 mg QD 30 mg Cohort: Abatacept/Upadacitinib 30 mg QD
    Started
    277
    277
    17
    20
    Entered Period 2 on Study Drug
    271
    276
    17
    19
    Upa Dose Switch From 30 mg to 15 mg QD
    0 [3]
    0 [4]
    12
    12
    No Upadacitinib Dose Switch
    0 [5]
    0 [6]
    5 [7]
    7 [8]
    Completed
    207
    208
    11
    12
    Not completed
    70
    69
    6
    8
         Consent withdrawn by subject
    15
    25
    2
    2
         Adverse Event
    20
    11
    1
    2
         COVID-19 Logistical Restrictions
    1
    -
    -
    -
         COVID-19 Infection
    5
    -
    -
    -
         Lost to follow-up
    6
    11
    1
    -
         Other, Not Specified
    23
    22
    2
    4
    Notes
    [2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
    Justification: Only participants continuing on to Period 2 are included in this table.
    [3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Milestone data are presented correctly in this table.
    [4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Milestone data are presented correctly in this table.
    [5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Milestone data are presented correctly in this table.
    [6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Milestone data are presented correctly in this table.
    [7] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Milestone data are presented correctly in this table.
    [8] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Milestone data are presented correctly in this table.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Primary Cohort: Upadacitinib 15 mg QD
    Reporting group description
    Period 1: One 15 mg upadacitinib oral tablet taken once per day (QD) for 24 weeks.

    Reporting group title
    Primary Cohort: Abatacept
    Reporting group description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20.

    Reporting group title
    30 mg Cohort: Upadacitinib 30 mg QD
    Reporting group description
    Period 1: One upadacitinib 30 mg oral tablet QD for 24 weeks.

    Reporting group title
    30 mg Cohort: Abatacept
    Reporting group description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20.

    Reporting group values
    Primary Cohort: Upadacitinib 15 mg QD Primary Cohort: Abatacept 30 mg Cohort: Upadacitinib 30 mg QD 30 mg Cohort: Abatacept Total
    Number of subjects
    303 309 21 23 656
    Age categorical
    Units: Subjects
        < 40 years
    30 31 5 2 68
        40 - 64 years
    209 207 10 17 443
        ≥ 65 years
    64 71 6 4 145
    Gender categorical
    Units: Subjects
        Female
    249 253 16 20 538
        Male
    54 56 5 3 118
    Race
    Units: Subjects
        White
    288 285 19 20 612
        Black or African American
    7 14 2 3 26
        American Indian or Alaska Native
    1 2 0 0 3
        Native Hawaiian or other Pacific Islander
    0 0 0 0 0
        Asian
    5 6 0 0 11
        Multiple
    2 2 0 0 4
        Other
    0 0 0 0 0
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    112 117 4 5 238
        Not Hispanic or Latino
    191 192 17 18 418
    Geographic Region
    Units: Subjects
        North America
    72 73 14 16 175
        South/Central America
    98 99 0 0 197
        Western Europe
    43 45 1 1 90
        Eastern Europe
    77 77 6 6 166
        Asia
    4 4 0 0 8
        Other
    9 11 0 0 20
    Disease Activity Score Based on C-reactive protein (CRP; DAS28 [CRP])
    The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score > 5.1 indicates high disease activity, a DAS28 score ≤ 3.2 indicates low disease activity, and a DAS28 score < 2.6 indicates clinical remission.
    Units: Subjects
        Score > 5.1
    224 241 15 19 499
        Score ≤ 5.1
    79 67 4 3 153
        Score Missing
    0 1 2 1 4

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Primary Cohort: Upadacitinib 15 mg QD
    Reporting group description
    Period 1: One 15 mg upadacitinib oral tablet taken once per day (QD) for 24 weeks.

    Reporting group title
    Primary Cohort: Abatacept
    Reporting group description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20.

    Reporting group title
    30 mg Cohort: Upadacitinib 30 mg QD
    Reporting group description
    Period 1: One upadacitinib 30 mg oral tablet QD for 24 weeks.

    Reporting group title
    30 mg Cohort: Abatacept
    Reporting group description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20.
    Reporting group title
    Primary Cohort: Upadacitinib 15 mg QD/Upadacitinib 15 mg QD
    Reporting group description
    Period 1: One 15 mg upadacitinib oral tablet QD for 24 weeks. Period 2: open label upadacitinib 15 mg QD for 192 weeks.

    Reporting group title
    Primary Cohort: Abatacept/Upadacitinib 15 mg QD
    Reporting group description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 15 mg QD for 192 weeks.

    Reporting group title
    30 mg Cohort: Upadacitinib 30 mg QD/Upadacitinib 30 mg QD
    Reporting group description
    Period 1: One upadacitinib 30 mg oral tablet QD for 24 weeks. Period 2: open label upadacitinib 30 mg (reduced to 15 mg per Amendment 5) QD for 192 weeks.

    Reporting group title
    30 mg Cohort: Abatacept/Upadacitinib 30 mg QD
    Reporting group description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 30 mg (reduced to 15 mg per Amendment 5) QD for 192 weeks.

    Primary: Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority)

    Close Top of page
    End point title
    Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) [1]
    End point description
    The Disease Activity Score (DAS) 28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity. Full Analysis Set: all randomized participants who received at least one dose of study drug; multiple imputation was used for missing data.
    End point type
    Primary
    End point timeframe
    Baseline and Week 12
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Primary and Secondary endpoints were analyzed in the Primary Cohorts only.
    End point values
    Primary Cohort: Upadacitinib 15 mg QD Primary Cohort: Abatacept
    Number of subjects analysed
    303
    309
    Units: units on a scale
        least squares mean (confidence interval 95%)
    -2.52 (-2.66 to -2.37)
    -2.00 (-2.14 to -1.85)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    In order to preserve Type I error, a step-down approach was used to test the primary and ranked secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance. Treatment Difference = Upadacitinib 15 mg - Abatacept
    Comparison groups
    Primary Cohort: Upadacitinib 15 mg QD v Primary Cohort: Abatacept
    Number of subjects included in analysis
    612
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [2]
    P-value
    < 0.001 [3]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    -0.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.69
         upper limit
    -0.35
    Notes
    [2] - The non-inferiority of upadacitinib 15 mg versus abatacept was tested using the 95% confidence interval (CI) of treatment difference against a non-inferiority margin of 0.6.
    [3] - The ANCOVA model included treatment as the fixed factor; corresponding baseline value and the stratification factor of prior bDMARD used as covariates.

    Secondary: Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Superiority)

    Close Top of page
    End point title
    Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Superiority) [4]
    End point description
    The Disease Activity Score (DAS) 28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 12
    Notes
    [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Primary and Secondary endpoints were analyzed in the Primary Cohorts only.
    End point values
    Primary Cohort: Upadacitinib 15 mg QD Primary Cohort: Abatacept
    Number of subjects analysed
    303
    309
    Units: units on a scale
        least squares mean (confidence interval 95%)
    -2.52 (-2.66 to -2.37)
    -2.00 (-2.14 to -1.85)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    In order to preserve Type I error, a step-down approach was used to test the primary and ranked secondary endpoints in a pre specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance. Treatment Difference = Upadacitinib 15 mg - Abatacept
    Comparison groups
    Primary Cohort: Upadacitinib 15 mg QD v Primary Cohort: Abatacept
    Number of subjects included in analysis
    612
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001 [5]
    Method
    ANCOVA
    Parameter type
    LS Mean Difference
    Point estimate
    -0.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.69
         upper limit
    -0.35
    Notes
    [5] - This comparison was a ranked secondary endpoint in the pre-specified multiplicity testing sequence. The ANCOVA model included treatment as the fixed factor; corresponding baseline value and the stratification factor of prior bDMARD used as covariates

    Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Superiority)

    Close Top of page
    End point title
    Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Superiority) [6]
    End point description
    The Disease Activity Score (DAS) 28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS 28 score less than 2.6 indicates clinical remission. Full Analysis Set: all randomized participants who received at least one dose of study drug; participants who prematurely discontinued study drug were considered non-responders after discontinuation.
    End point type
    Secondary
    End point timeframe
    At Week 12
    Notes
    [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Primary and Secondary endpoints were analyzed in the Primary Cohorts only.
    End point values
    Primary Cohort: Upadacitinib 15 mg QD Primary Cohort: Abatacept
    Number of subjects analysed
    303
    309
    Units: percentage of participants
        number (confidence interval 95%)
    30.0 (24.9 to 35.2)
    13.3 (9.5 to 17.1)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    In order to preserve Type I error, a step-down approach was used to test the primary and ranked secondary endpoints in a pre-specified order where statistical significance at the 0.05 level could be claimed for a lower ranked endpoint only if the previous endpoint in the sequence met the requirements of significance. Treatment Difference = Upadacitinib 15 mg - Abatacept
    Comparison groups
    Primary Cohort: Upadacitinib 15 mg QD v Primary Cohort: Abatacept
    Number of subjects included in analysis
    612
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001 [7]
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Mean Difference
    Point estimate
    16.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    10.4
         upper limit
    23.2
    Notes
    [7] - This comparison was a ranked secondary endpoint in the pre-specified multiplicity testing sequence. The stratification factor of prior failed bDMARD was used.

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From informed consent until discontinuation of study drug administration (up to 24 weeks for Period 1 and up to 192 weeks for Period 2), plus 70 days.
    Adverse event reporting additional description
    Per protocol, for analysis of Period 1 safety data, the Primary and 30 mg Cohorts receiving abatacept were combined.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    22.0
    Reporting groups
    Reporting group title
    Period 2, Primary Cohort:Abatacept/Upadacitinib (Upa) 15 mg QD
    Reporting group description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 15 mg QD for 192 weeks.

    Reporting group title
    Period 1, 30 mg Cohort: Upa 30 mg QD
    Reporting group description
    Period 1: One upadacitinib 30 mg oral tablet QD for 24 weeks.

    Reporting group title
    Period 1, Primary Cohort: Upa 15 mg QD
    Reporting group description
    Period 1: One 15 mg upadacitinib oral tablet QD for 24 weeks.

    Reporting group title
    Period 1, Primary and 30 mg Cohorts: Abatacept
    Reporting group description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20.

    Reporting group title
    Period 2, 30 mg Cohort: Abatacept/Upa 30 mg QD/Upa 15 mg QD
    Reporting group description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 30 mg QD followed by upadacitinib 15 mg QD for a total of 192 weeks.

    Reporting group title
    Period 2, 30mg Cohort: Upa 30 mg QD/Upa 30 mg QD
    Reporting group description
    Period 1: One upadacitinib 30 mg oral tablet taken once per day (QD) for 24 weeks. Period 2: open label upadacitinib 30 mg QD for 192 weeks.

    Reporting group title
    Period 2, 30 mg Cohort: Abatacept/Upa 30 mg QD
    Reporting group description
    Period 1: 500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) IV infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20. Period 2: open label upadacitinib 30 mg QD for 192 weeks.

    Reporting group title
    Period 2, 30 mg Cohort: Upa 30 mg QD/Upa 30 mg QD/Upa 15 mg QD
    Reporting group description
    Period 1: One upadacitinib 30 mg oral tablet QD for 24 weeks. Period 2: open label upadacitinib 30 mg QD followed by upadacitinib 15 mg QD for a total of 192 weeks.

    Reporting group title
    Period 2, Primary Cohort: Upa 15 mg QD/Upa 15 mg QD
    Reporting group description
    Period 1: One 15 mg upadacitinib oral tablet QD for 24 weeks. Period 2: open label upadacitinib 15 mg QD for 192 weeks.

    Serious adverse events
    Period 2, Primary Cohort:Abatacept/Upadacitinib (Upa) 15 mg QD Period 1, 30 mg Cohort: Upa 30 mg QD Period 1, Primary Cohort: Upa 15 mg QD Period 1, Primary and 30 mg Cohorts: Abatacept Period 2, 30 mg Cohort: Abatacept/Upa 30 mg QD/Upa 15 mg QD Period 2, 30mg Cohort: Upa 30 mg QD/Upa 30 mg QD Period 2, 30 mg Cohort: Abatacept/Upa 30 mg QD Period 2, 30 mg Cohort: Upa 30 mg QD/Upa 30 mg QD/Upa 15 mg QD Period 2, Primary Cohort: Upa 15 mg QD/Upa 15 mg QD
    Total subjects affected by serious adverse events
         subjects affected / exposed
    68 / 276 (24.64%)
    4 / 21 (19.05%)
    12 / 303 (3.96%)
    7 / 332 (2.11%)
    3 / 12 (25.00%)
    6 / 17 (35.29%)
    4 / 19 (21.05%)
    2 / 12 (16.67%)
    64 / 271 (23.62%)
         number of deaths (all causes)
    7
    0
    2
    1
    1
    0
    0
    0
    16
         number of deaths resulting from adverse events
    1
    0
    0
    0
    0
    0
    0
    0
    1
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    COLORECTAL ADENOMA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INTESTINAL METASTASIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    INVASIVE DUCTAL BREAST CARCINOMA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INVASIVE BREAST CARCINOMA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    KAPOSI'S SARCOMA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LUNG ADENOCARCINOMA STAGE IV
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    MALIGNANT MELANOMA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LUNG NEOPLASM MALIGNANT
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RECTAL CANCER
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    OVARIAN EPITHELIAL CANCER METASTATIC
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NON-SECRETORY ADENOMA OF PITUITARY
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    METASTASES TO LIVER
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    MANTLE CELL LYMPHOMA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    UTERINE LEIOMYOMA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    UTERINE CANCER
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SMALL CELL LUNG CANCER
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    AORTIC INTRAMURAL HAEMATOMA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DEEP VEIN THROMBOSIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPERTENSION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PERIPHERAL ARTERY OCCLUSION
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Surgical and medical procedures
    ARTHRODESIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    KNEE ARTHROPLASTY
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    WOUND DRAINAGE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    ABORTION SPONTANEOUS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    CHEST PAIN
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DEATH
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    FAT NECROSIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MULTIPLE ORGAN DYSFUNCTION SYNDROME
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    PAIN
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    CERVICAL DYSPLASIA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ADNEXA UTERI CYST
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ENDOMETRIOSIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INTERMENSTRUAL BLEEDING
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MENOMETRORRHAGIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PELVIC ORGAN PROLAPSE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    UTERINE HAEMORRHAGE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    VAGINAL PROLAPSE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    ACUTE RESPIRATORY DISTRESS SYNDROME
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    ACUTE RESPIRATORY FAILURE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CHRONIC OBSTRUCTIVE PULMONARY DISEASE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ASTHMA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DYSPHONIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    EPISTAXIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PLEURAL EFFUSION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONITIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    PULMONARY EMBOLISM
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    UPPER-AIRWAY COUGH SYNDROME
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    ACUTE PSYCHOSIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ALCOHOL WITHDRAWAL SYNDROME
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ALCOHOL ABUSE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    ARTHROPOD BITE
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COMMINUTED FRACTURE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FEMORAL NECK FRACTURE
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FEMUR FRACTURE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HIP FRACTURE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FOREARM FRACTURE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FIBULA FRACTURE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    JOINT DISLOCATION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LOWER LIMB FRACTURE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MENISCUS INJURY
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PATELLA FRACTURE
         subjects affected / exposed
    1 / 276 (0.36%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PELVIC FRACTURE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RADIUS FRACTURE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    UPPER LIMB FRACTURE
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    TIBIA FRACTURE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    TENDON RUPTURE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SPINAL COMPRESSION FRACTURE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SYNOVIAL RUPTURE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    WRIST FRACTURE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    ATRIAL FIBRILLATION
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ANGINA UNSTABLE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SUPRAVENTRICULAR TACHYCARDIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CARDIO-RESPIRATORY ARREST
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CARDIAC FAILURE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    CARDIAC ARREST
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    ATRIOVENTRICULAR BLOCK COMPLETE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    CAUDA EQUINA SYNDROME
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CAROTID ARTERY STENOSIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CEREBROVASCULAR ACCIDENT
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIZZINESS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HEADACHE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LUMBAR RADICULOPATHY
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ISCHAEMIC STROKE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HEMIPARESIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MIGRAINE
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SPONDYLITIC MYELOPATHY
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OCCIPITAL NEURALGIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MOTOR NEURONE DISEASE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SYNCOPE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    ANAEMIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NEUTROPENIA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    VERTIGO POSITIONAL
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    RETINAL DETACHMENT
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DACRYOSTENOSIS ACQUIRED
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CATARACT
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    ABDOMINAL PAIN
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ENTERITIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DYSPHAGIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIVERTICULAR PERFORATION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIARRHOEA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GASTRIC DISORDER
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INTRA-ABDOMINAL HAEMORRHAGE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INGUINAL HERNIA
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ILEUS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HAEMORRHOIDS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LARGE INTESTINE POLYP
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NAUSEA
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PANCREATITIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PANCREATITIS ACUTE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    VOLVULUS OF SMALL BOWEL
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    VOMITING
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    BILIARY COLIC
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BILIARY OBSTRUCTION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CHOLECYSTITIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CHOLELITHIASIS
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    ACUTE KIDNEY INJURY
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endocrine disorders
    GOITRE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPERPARATHYROIDISM
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    ARTHRALGIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FOOT DEFORMITY
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CERVICAL SPINAL STENOSIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FRACTURE PAIN
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INTERVERTEBRAL DISC PROTRUSION
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INTERVERTEBRAL DISC DEGENERATION
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OSTEOARTHRITIS
         subjects affected / exposed
    5 / 276 (1.81%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RHEUMATOID ARTHRITIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ROTATOR CUFF SYNDROME
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SPINAL OSTEOARTHRITIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SPINAL STENOSIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SYNOVIAL CYST
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    BACTERIAL SEPSIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ARTHRITIS BACTERIAL
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ABSCESS SOFT TISSUE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    4 / 276 (1.45%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    6 / 271 (2.21%)
         occurrences causally related to treatment / all
    1 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    1 / 6
         deaths causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 4
    BURSITIS INFECTIVE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BRONCHITIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BONE ABSCESS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COVID-19 PNEUMONIA
         subjects affected / exposed
    6 / 276 (2.17%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    9 / 271 (3.32%)
         occurrences causally related to treatment / all
    1 / 6
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    2 / 9
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    CELLULITIS STAPHYLOCOCCAL
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DEVICE RELATED INFECTION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ESCHERICHIA URINARY TRACT INFECTION
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIVERTICULITIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GASTROENTERITIS VIRAL
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INFECTIOUS PLEURAL EFFUSION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LUNG ABSCESS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MEDICAL DEVICE SITE ABSCESS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OPHTHALMIC HERPES ZOSTER
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OSTEOMYELITIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONIA
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    2 / 332 (0.60%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 0
    1 / 1
    1 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONIA BACTERIAL
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONIA VIRAL
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    POSTOPERATIVE WOUND INFECTION
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PYELONEPHRITIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PYELONEPHRITIS CHRONIC
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RESPIRATORY TRACT INFECTION
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SEPSIS
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SOFT TISSUE INFECTION
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SKIN INFECTION
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SEPTIC SHOCK
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    STAPHYLOCOCCAL BACTERAEMIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    STAPHYLOCOCCAL INFECTION
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    URINARY TRACT INFECTION
         subjects affected / exposed
    4 / 276 (1.45%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    3 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    HYPONATRAEMIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIABETIC KETOACIDOSIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DEHYDRATION
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CENTRAL OBESITY
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Period 2, Primary Cohort:Abatacept/Upadacitinib (Upa) 15 mg QD Period 1, 30 mg Cohort: Upa 30 mg QD Period 1, Primary Cohort: Upa 15 mg QD Period 1, Primary and 30 mg Cohorts: Abatacept Period 2, 30 mg Cohort: Abatacept/Upa 30 mg QD/Upa 15 mg QD Period 2, 30mg Cohort: Upa 30 mg QD/Upa 30 mg QD Period 2, 30 mg Cohort: Abatacept/Upa 30 mg QD Period 2, 30 mg Cohort: Upa 30 mg QD/Upa 30 mg QD/Upa 15 mg QD Period 2, Primary Cohort: Upa 15 mg QD/Upa 15 mg QD
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    221 / 276 (80.07%)
    13 / 21 (61.90%)
    174 / 303 (57.43%)
    149 / 332 (44.88%)
    9 / 12 (75.00%)
    15 / 17 (88.24%)
    17 / 19 (89.47%)
    7 / 12 (58.33%)
    221 / 271 (81.55%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    SKIN PAPILLOMA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    1
    0
    2
    0
    0
    0
    1
    0
    1
    SEBORRHOEIC KERATOSIS
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    1
    0
    0
    0
    HAEMANGIOMA OF SPLEEN
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    UTERINE LEIOMYOMA
         subjects affected / exposed
    4 / 276 (1.45%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    4
    0
    0
    0
    0
    0
    1
    0
    0
    Vascular disorders
    HYPERTENSION
         subjects affected / exposed
    25 / 276 (9.06%)
    0 / 21 (0.00%)
    16 / 303 (5.28%)
    11 / 332 (3.31%)
    0 / 12 (0.00%)
    4 / 17 (23.53%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    24 / 271 (8.86%)
         occurrences all number
    27
    0
    16
    11
    0
    4
    0
    0
    26
    General disorders and administration site conditions
    NON-CARDIAC CHEST PAIN
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    0
    0
    CHEST PAIN
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    3
    0
    1
    2
    0
    1
    0
    0
    1
    FATIGUE
         subjects affected / exposed
    7 / 276 (2.54%)
    0 / 21 (0.00%)
    3 / 303 (0.99%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    7 / 271 (2.58%)
         occurrences all number
    8
    0
    3
    2
    0
    1
    0
    0
    7
    FEELING HOT
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    PERIPHERAL SWELLING
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    1
    0
    1
    1
    0
    1
    0
    0
    3
    PYREXIA
         subjects affected / exposed
    6 / 276 (2.17%)
    2 / 21 (9.52%)
    2 / 303 (0.66%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    7 / 271 (2.58%)
         occurrences all number
    9
    2
    2
    3
    0
    0
    1
    0
    7
    SWELLING
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    0
    Immune system disorders
    DRUG HYPERSENSITIVITY
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    1
    0
    0
    0
    0
    2
    0
    0
    1
    Reproductive system and breast disorders
    CYSTOCELE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    0
    0
    0
    Respiratory, thoracic and mediastinal disorders
    ASTHMA
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    1
    0
    2
    OROPHARYNGEAL PAIN
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    2
    0
    1
    1
    0
    2
    1
    0
    1
    INTERSTITIAL LUNG DISEASE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    0
    0
    0
    DYSPHONIA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    2
    0
    2
    COUGH
         subjects affected / exposed
    12 / 276 (4.35%)
    2 / 21 (9.52%)
    7 / 303 (2.31%)
    8 / 332 (2.41%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    17 / 271 (6.27%)
         occurrences all number
    13
    2
    7
    8
    0
    1
    1
    0
    20
    BRONCHIECTASIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    1 / 271 (0.37%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    1
    1
    NASAL CONGESTION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    0
    0
    0
    2
    0
    1
    0
    0
    3
    PLEURAL EFFUSION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    PULMONARY MASS
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    3 / 271 (1.11%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    1
    3
    RHINORRHOEA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    1
    0
    0
    1
    0
    1
    0
    0
    2
    Psychiatric disorders
    ANXIETY
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    6 / 271 (2.21%)
         occurrences all number
    2
    0
    1
    3
    0
    0
    1
    0
    8
    AFFECT LABILITY
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    DEPRESSION
         subjects affected / exposed
    6 / 276 (2.17%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    2 / 332 (0.60%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    10 / 271 (3.69%)
         occurrences all number
    6
    0
    0
    2
    1
    0
    1
    0
    14
    PANIC ATTACK
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    1
    0
    0
    INSOMNIA
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    5 / 271 (1.85%)
         occurrences all number
    3
    0
    1
    0
    0
    1
    0
    0
    5
    DEPRESSION SUICIDAL
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Investigations
    ALANINE AMINOTRANSFERASE INCREASED
         subjects affected / exposed
    13 / 276 (4.71%)
    0 / 21 (0.00%)
    14 / 303 (4.62%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    15 / 271 (5.54%)
         occurrences all number
    24
    0
    20
    3
    0
    0
    1
    0
    20
    ASPARTATE AMINOTRANSFERASE INCREASED
         subjects affected / exposed
    13 / 276 (4.71%)
    0 / 21 (0.00%)
    12 / 303 (3.96%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    17 / 271 (6.27%)
         occurrences all number
    22
    0
    18
    1
    0
    0
    0
    0
    28
    BLOOD CREATINE PHOSPHOKINASE INCREASED
         subjects affected / exposed
    31 / 276 (11.23%)
    0 / 21 (0.00%)
    9 / 303 (2.97%)
    6 / 332 (1.81%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    16 / 271 (5.90%)
         occurrences all number
    48
    0
    10
    7
    0
    1
    0
    0
    25
    BLOOD CREATININE INCREASED
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    3
    0
    1
    0
    0
    0
    1
    0
    5
    WEIGHT INCREASED
         subjects affected / exposed
    14 / 276 (5.07%)
    0 / 21 (0.00%)
    6 / 303 (1.98%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    13 / 271 (4.80%)
         occurrences all number
    19
    0
    7
    3
    0
    2
    1
    0
    18
    SCAN ADRENAL GLAND ABNORMAL
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    WHITE BLOOD CELLS URINE POSITIVE
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    1
    0
    0
    BLOOD PRESSURE INCREASED
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    2
    0
    0
    0
    0
    1
    0
    0
    6
    BLOOD TRIGLYCERIDES INCREASED
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    2 / 19 (10.53%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    1
    0
    2
    0
    0
    0
    2
    0
    2
    ELECTROCARDIOGRAM ABNORMAL
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    1
    HAEMOGLOBIN DECREASED
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    5
    0
    0
    0
    0
    1
    0
    0
    3
    HEPATIC ENZYME INCREASED
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    1
    0
    3
    HIGH DENSITY LIPOPROTEIN DECREASED
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    LIVER FUNCTION TEST INCREASED
         subjects affected / exposed
    1 / 276 (0.36%)
    1 / 21 (4.76%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    1
    1
    0
    1
    0
    2
    0
    0
    3
    Injury, poisoning and procedural complications
    CONTUSION
         subjects affected / exposed
    0 / 276 (0.00%)
    1 / 21 (4.76%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    0
    1
    1
    0
    1
    0
    0
    0
    4
    BONE CONTUSION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    0
    2
    BURNS SECOND DEGREE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    1
    CORNEAL ABRASION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    FALL
         subjects affected / exposed
    14 / 276 (5.07%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    12 / 271 (4.43%)
         occurrences all number
    15
    0
    2
    2
    0
    2
    1
    0
    13
    LIGAMENT RUPTURE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    0
    1
    SCRATCH
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    SKIN LACERATION
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    2
    0
    1
    1
    0
    1
    0
    0
    1
    TOOTH FRACTURE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    4
    Congenital, familial and genetic disorders
    TYPE V HYPERLIPIDAEMIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Cardiac disorders
    ATRIOVENTRICULAR BLOCK FIRST DEGREE
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    2
    0
    0
    0
    0
    1
    0
    0
    1
    ATRIAL FIBRILLATION
         subjects affected / exposed
    4 / 276 (1.45%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    5
    0
    1
    0
    1
    0
    0
    0
    1
    CARDIOMYOPATHY
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    0
    0
    0
    MITRAL VALVE INCOMPETENCE
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    3
    0
    1
    0
    1
    0
    0
    0
    2
    SUPRAVENTRICULAR TACHYCARDIA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    TACHYCARDIA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    1
    0
    0
    0
    0
    1
    0
    0
    4
    TRICUSPID VALVE INCOMPETENCE
         subjects affected / exposed
    4 / 276 (1.45%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    4
    0
    0
    0
    1
    0
    0
    0
    2
    Nervous system disorders
    SCIATICA
         subjects affected / exposed
    8 / 276 (2.90%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    6 / 271 (2.21%)
         occurrences all number
    10
    0
    2
    1
    0
    1
    0
    0
    10
    CARPAL TUNNEL SYNDROME
         subjects affected / exposed
    5 / 276 (1.81%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    5
    0
    0
    4
    0
    0
    1
    0
    2
    DIZZINESS
         subjects affected / exposed
    2 / 276 (0.72%)
    1 / 21 (4.76%)
    2 / 303 (0.66%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    2
    1
    3
    2
    0
    1
    2
    0
    2
    HEADACHE
         subjects affected / exposed
    12 / 276 (4.35%)
    0 / 21 (0.00%)
    10 / 303 (3.30%)
    10 / 332 (3.01%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    11 / 271 (4.06%)
         occurrences all number
    17
    0
    10
    11
    0
    1
    1
    0
    11
    PARAESTHESIA
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    3
    0
    1
    1
    0
    1
    0
    0
    3
    TREMOR
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    0
    0
    0
    SYNCOPE
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    2
    0
    2
    0
    0
    0
    1
    0
    2
    Blood and lymphatic system disorders
    ANAEMIA
         subjects affected / exposed
    15 / 276 (5.43%)
    1 / 21 (4.76%)
    3 / 303 (0.99%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    10 / 271 (3.69%)
         occurrences all number
    15
    1
    4
    3
    0
    0
    0
    0
    13
    IRON DEFICIENCY ANAEMIA
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    1
    0
    3
    NEUTROPENIA
         subjects affected / exposed
    14 / 276 (5.07%)
    0 / 21 (0.00%)
    5 / 303 (1.65%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    9 / 271 (3.32%)
         occurrences all number
    26
    0
    5
    2
    0
    0
    0
    0
    13
    LEUKOCYTOSIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    0
    Ear and labyrinth disorders
    TINNITUS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    2 / 271 (0.74%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    1
    2
    Eye disorders
    EYELID PTOSIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    CATARACT
         subjects affected / exposed
    6 / 276 (2.17%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    8
    0
    0
    0
    0
    1
    1
    0
    4
    EYE HAEMATOMA
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    GLAUCOMA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    1
    0
    1
    0
    0
    1
    0
    0
    2
    Gastrointestinal disorders
    ABDOMINAL PAIN
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    3 / 303 (0.99%)
    4 / 332 (1.20%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    3
    0
    3
    4
    0
    0
    1
    0
    3
    CONSTIPATION
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    3 / 303 (0.99%)
    4 / 332 (1.20%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    5
    0
    4
    4
    0
    1
    0
    0
    3
    DIARRHOEA
         subjects affected / exposed
    14 / 276 (5.07%)
    1 / 21 (4.76%)
    8 / 303 (2.64%)
    13 / 332 (3.92%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    9 / 271 (3.32%)
         occurrences all number
    17
    2
    9
    13
    0
    0
    0
    0
    9
    HAEMORRHOIDS
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    2 / 332 (0.60%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    3
    0
    2
    2
    1
    0
    0
    0
    1
    DUODENOGASTRIC REFLUX
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    2
    0
    0
    0
    1
    0
    0
    0
    1
    DYSPEPSIA
         subjects affected / exposed
    3 / 276 (1.09%)
    1 / 21 (4.76%)
    4 / 303 (1.32%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    5 / 271 (1.85%)
         occurrences all number
    3
    1
    4
    1
    0
    0
    1
    0
    6
    GASTRITIS
         subjects affected / exposed
    11 / 276 (3.99%)
    1 / 21 (4.76%)
    3 / 303 (0.99%)
    2 / 332 (0.60%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    6 / 271 (2.21%)
         occurrences all number
    14
    1
    4
    2
    1
    0
    0
    0
    8
    DIVERTICULUM INTESTINAL
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    1
    0
    1
    0
    0
    0
    0
    LARGE INTESTINE POLYP
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    2
    0
    1
    0
    1
    0
    0
    0
    0
    NAUSEA
         subjects affected / exposed
    8 / 276 (2.90%)
    2 / 21 (9.52%)
    11 / 303 (3.63%)
    8 / 332 (2.41%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    15 / 271 (5.54%)
         occurrences all number
    8
    2
    11
    13
    0
    1
    0
    0
    16
    PANCREATIC CYST
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    STOMATITIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    1
    3
    0
    1
    0
    0
    0
    VOMITING
         subjects affected / exposed
    4 / 276 (1.45%)
    2 / 21 (9.52%)
    3 / 303 (0.99%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    7 / 271 (2.58%)
         occurrences all number
    5
    2
    3
    1
    0
    1
    0
    0
    8
    Hepatobiliary disorders
    CHOLELITHIASIS
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    3
    0
    1
    0
    0
    3
    0
    0
    3
    HEPATIC STEATOSIS
         subjects affected / exposed
    11 / 276 (3.99%)
    0 / 21 (0.00%)
    4 / 303 (1.32%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    8 / 271 (2.95%)
         occurrences all number
    11
    0
    4
    0
    1
    1
    0
    0
    8
    Skin and subcutaneous tissue disorders
    DERMATITIS ALLERGIC
         subjects affected / exposed
    5 / 276 (1.81%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    5
    0
    0
    0
    0
    1
    0
    0
    2
    DERMATITIS CONTACT
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    1
    1
    0
    1
    0
    0
    2
    ERYTHEMA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    1
    0
    0
    0
    0
    1
    0
    0
    1
    NIGHT SWEATS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    1
    PHOTODERMATOSIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    PRURITUS
         subjects affected / exposed
    2 / 276 (0.72%)
    1 / 21 (4.76%)
    1 / 303 (0.33%)
    5 / 332 (1.51%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    2
    1
    1
    6
    0
    1
    0
    0
    2
    ACTINIC KERATOSIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    RASH
         subjects affected / exposed
    4 / 276 (1.45%)
    2 / 21 (9.52%)
    2 / 303 (0.66%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    2 / 19 (10.53%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    4
    2
    2
    1
    0
    2
    2
    0
    1
    ROSACEA
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    3
    0
    0
    1
    0
    0
    1
    0
    1
    Renal and urinary disorders
    CYSTITIS NONINFECTIVE
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    BLADDER HYPERTROPHY
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    RENAL CYST
         subjects affected / exposed
    4 / 276 (1.45%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    2 / 271 (0.74%)
         occurrences all number
    4
    0
    0
    0
    1
    0
    0
    1
    2
    URETHRAL STENOSIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Musculoskeletal and connective tissue disorders
    COSTOCHONDRITIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    0
    0
    1
    1
    0
    1
    0
    0
    3
    BACK PAIN
         subjects affected / exposed
    20 / 276 (7.25%)
    0 / 21 (0.00%)
    6 / 303 (1.98%)
    10 / 332 (3.01%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    18 / 271 (6.64%)
         occurrences all number
    25
    0
    6
    10
    0
    1
    1
    0
    20
    ARTHRALGIA
         subjects affected / exposed
    15 / 276 (5.43%)
    2 / 21 (9.52%)
    3 / 303 (0.99%)
    6 / 332 (1.81%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    15 / 271 (5.54%)
         occurrences all number
    15
    2
    3
    7
    0
    1
    1
    0
    16
    FLANK PAIN
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    1
    SPINAL OSTEOARTHRITIS
         subjects affected / exposed
    5 / 276 (1.81%)
    0 / 21 (0.00%)
    3 / 303 (0.99%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    9 / 271 (3.32%)
         occurrences all number
    5
    0
    3
    0
    0
    0
    1
    0
    9
    SJOGREN'S SYNDROME
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    1
    0
    0
    0
    RHEUMATOID ARTHRITIS
         subjects affected / exposed
    32 / 276 (11.59%)
    3 / 21 (14.29%)
    11 / 303 (3.63%)
    15 / 332 (4.52%)
    1 / 12 (8.33%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    27 / 271 (9.96%)
         occurrences all number
    57
    4
    13
    15
    1
    1
    0
    0
    43
    OSTEOPOROSIS
         subjects affected / exposed
    6 / 276 (2.17%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    6
    0
    1
    0
    0
    0
    1
    0
    4
    OSTEOPENIA
         subjects affected / exposed
    5 / 276 (1.81%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    5
    0
    0
    1
    0
    1
    0
    0
    4
    OSTEOARTHRITIS
         subjects affected / exposed
    18 / 276 (6.52%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    3 / 332 (0.90%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    11 / 271 (4.06%)
         occurrences all number
    21
    0
    2
    3
    1
    0
    0
    0
    13
    MUSCULOSKELETAL CHEST PAIN
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    0
    0
    1
    2
    0
    0
    1
    0
    2
    MUSCLE SPASMS
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    4 / 303 (1.32%)
    6 / 332 (1.81%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    2
    0
    4
    6
    0
    2
    1
    0
    2
    GREATER TROCHANTERIC PAIN SYNDROME
         subjects affected / exposed
    6 / 276 (2.17%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    2 / 19 (10.53%)
    0 / 12 (0.00%)
    7 / 271 (2.58%)
         occurrences all number
    6
    0
    1
    2
    0
    0
    2
    0
    7
    SPONDYLOLISTHESIS
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    1
    0
    1
    TRIGGER FINGER
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    1
    Infections and infestations
    CANDIDA INFECTION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    ASYMPTOMATIC COVID-19
         subjects affected / exposed
    7 / 276 (2.54%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    7
    0
    0
    0
    0
    0
    1
    0
    4
    BRONCHITIS
         subjects affected / exposed
    26 / 276 (9.42%)
    1 / 21 (4.76%)
    8 / 303 (2.64%)
    13 / 332 (3.92%)
    0 / 12 (0.00%)
    3 / 17 (17.65%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    16 / 271 (5.90%)
         occurrences all number
    33
    1
    8
    13
    0
    3
    1
    0
    18
    COVID-19
         subjects affected / exposed
    47 / 276 (17.03%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    5 / 12 (41.67%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    64 / 271 (23.62%)
         occurrences all number
    53
    0
    0
    0
    5
    0
    0
    1
    69
    CYSTITIS
         subjects affected / exposed
    10 / 276 (3.62%)
    0 / 21 (0.00%)
    4 / 303 (1.32%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    2 / 19 (10.53%)
    0 / 12 (0.00%)
    9 / 271 (3.32%)
         occurrences all number
    16
    0
    5
    3
    0
    0
    2
    0
    10
    EAR INFECTION
         subjects affected / exposed
    7 / 276 (2.54%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    7 / 271 (2.58%)
         occurrences all number
    7
    0
    0
    1
    1
    0
    0
    0
    7
    GASTROENTERITIS
         subjects affected / exposed
    12 / 276 (4.35%)
    0 / 21 (0.00%)
    12 / 303 (3.96%)
    4 / 332 (1.20%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    9 / 271 (3.32%)
         occurrences all number
    13
    0
    14
    4
    0
    0
    1
    0
    9
    HERPES SIMPLEX
         subjects affected / exposed
    2 / 276 (0.72%)
    0 / 21 (0.00%)
    3 / 303 (0.99%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    4
    0
    3
    1
    0
    1
    0
    0
    3
    NASOPHARYNGITIS
         subjects affected / exposed
    28 / 276 (10.14%)
    1 / 21 (4.76%)
    22 / 303 (7.26%)
    14 / 332 (4.22%)
    1 / 12 (8.33%)
    2 / 17 (11.76%)
    4 / 19 (21.05%)
    0 / 12 (0.00%)
    37 / 271 (13.65%)
         occurrences all number
    39
    1
    22
    15
    1
    2
    5
    0
    57
    INFLUENZA
         subjects affected / exposed
    10 / 276 (3.62%)
    0 / 21 (0.00%)
    4 / 303 (1.32%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    2 / 19 (10.53%)
    0 / 12 (0.00%)
    12 / 271 (4.43%)
         occurrences all number
    14
    0
    5
    2
    0
    2
    2
    0
    12
    LATENT TUBERCULOSIS
         subjects affected / exposed
    14 / 276 (5.07%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    1 / 12 (8.33%)
    6 / 271 (2.21%)
         occurrences all number
    14
    0
    0
    0
    0
    0
    0
    1
    6
    LOCALISED INFECTION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    1
    0
    4
    HERPES ZOSTER
         subjects affected / exposed
    35 / 276 (12.68%)
    0 / 21 (0.00%)
    3 / 303 (0.99%)
    4 / 332 (1.20%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    24 / 271 (8.86%)
         occurrences all number
    35
    0
    3
    4
    0
    1
    0
    0
    27
    ONYCHOMYCOSIS
         subjects affected / exposed
    4 / 276 (1.45%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    4
    0
    2
    0
    0
    0
    1
    0
    4
    OPHTHALMIC HERPES ZOSTER
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    2
    0
    0
    ORAL CANDIDIASIS
         subjects affected / exposed
    1 / 276 (0.36%)
    1 / 21 (4.76%)
    3 / 303 (0.99%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    2
    1
    3
    1
    0
    1
    0
    0
    9
    PERIODONTITIS
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    1
    0
    2
    RHINITIS
         subjects affected / exposed
    4 / 276 (1.45%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    5
    0
    0
    1
    0
    1
    0
    0
    4
    PHARYNGITIS STREPTOCOCCAL
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    1
    0
    1
    0
    0
    0
    1
    0
    2
    PNEUMONIA
         subjects affected / exposed
    3 / 276 (1.09%)
    0 / 21 (0.00%)
    3 / 303 (0.99%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    2 / 19 (10.53%)
    0 / 12 (0.00%)
    6 / 271 (2.21%)
         occurrences all number
    3
    0
    3
    3
    0
    1
    2
    0
    6
    POST PROCEDURAL CELLULITIS
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    RESPIRATORY TRACT INFECTION
         subjects affected / exposed
    10 / 276 (3.62%)
    0 / 21 (0.00%)
    1 / 303 (0.33%)
    2 / 332 (0.60%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    7 / 271 (2.58%)
         occurrences all number
    11
    0
    1
    2
    0
    0
    1
    0
    8
    PHARYNGITIS
         subjects affected / exposed
    8 / 276 (2.90%)
    0 / 21 (0.00%)
    4 / 303 (1.32%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    9 / 271 (3.32%)
         occurrences all number
    9
    0
    4
    3
    0
    1
    0
    0
    9
    SINUSITIS
         subjects affected / exposed
    10 / 276 (3.62%)
    2 / 21 (9.52%)
    5 / 303 (1.65%)
    5 / 332 (1.51%)
    0 / 12 (0.00%)
    2 / 17 (11.76%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    7 / 271 (2.58%)
         occurrences all number
    10
    2
    6
    5
    0
    2
    3
    0
    9
    STAPHYLOCOCCAL INFECTION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    1
    TOOTH INFECTION
         subjects affected / exposed
    6 / 276 (2.17%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    1 / 332 (0.30%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    6
    0
    2
    2
    1
    0
    2
    0
    4
    UPPER RESPIRATORY TRACT INFECTION
         subjects affected / exposed
    32 / 276 (11.59%)
    0 / 21 (0.00%)
    26 / 303 (8.58%)
    15 / 332 (4.52%)
    2 / 12 (16.67%)
    4 / 17 (23.53%)
    5 / 19 (26.32%)
    1 / 12 (8.33%)
    30 / 271 (11.07%)
         occurrences all number
    49
    0
    31
    18
    2
    4
    5
    1
    46
    VIRAL UPPER RESPIRATORY TRACT INFECTION
         subjects affected / exposed
    4 / 276 (1.45%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    2 / 271 (0.74%)
         occurrences all number
    4
    0
    0
    0
    0
    0
    1
    0
    2
    VULVOVAGINAL MYCOTIC INFECTION
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    3 / 332 (0.90%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    3
    0
    1
    0
    0
    0
    URINARY TRACT INFECTION
         subjects affected / exposed
    40 / 276 (14.49%)
    1 / 21 (4.76%)
    20 / 303 (6.60%)
    22 / 332 (6.63%)
    1 / 12 (8.33%)
    2 / 17 (11.76%)
    3 / 19 (15.79%)
    1 / 12 (8.33%)
    40 / 271 (14.76%)
         occurrences all number
    75
    1
    27
    28
    1
    3
    8
    1
    67
    Metabolism and nutrition disorders
    DECREASED APPETITE
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    1 / 332 (0.30%)
    1 / 12 (8.33%)
    0 / 17 (0.00%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    3 / 271 (1.11%)
         occurrences all number
    1
    0
    2
    1
    1
    0
    0
    0
    3
    HYPOKALAEMIA
         subjects affected / exposed
    1 / 276 (0.36%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    0 / 271 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    1
    0
    0
    0
    HYPERCHOLESTEROLAEMIA
         subjects affected / exposed
    8 / 276 (2.90%)
    0 / 21 (0.00%)
    3 / 303 (0.99%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    0 / 17 (0.00%)
    1 / 19 (5.26%)
    0 / 12 (0.00%)
    13 / 271 (4.80%)
         occurrences all number
    8
    0
    3
    0
    0
    0
    1
    0
    15
    DIABETES MELLITUS
         subjects affected / exposed
    5 / 276 (1.81%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    4 / 332 (1.20%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    4 / 271 (1.48%)
         occurrences all number
    6
    0
    2
    4
    0
    1
    0
    0
    4
    DEHYDRATION
         subjects affected / exposed
    0 / 276 (0.00%)
    0 / 21 (0.00%)
    0 / 303 (0.00%)
    1 / 332 (0.30%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    1 / 271 (0.37%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    1
    VITAMIN D DEFICIENCY
         subjects affected / exposed
    8 / 276 (2.90%)
    0 / 21 (0.00%)
    2 / 303 (0.66%)
    0 / 332 (0.00%)
    0 / 12 (0.00%)
    1 / 17 (5.88%)
    0 / 19 (0.00%)
    0 / 12 (0.00%)
    7 / 271 (2.58%)
         occurrences all number
    8
    0
    2
    0
    0
    1
    0
    0
    7

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    31 Aug 2016
    The study design was updated from a 24-week randomized, double-blind, parallel group active-controlled treatment period to 12-weeks in Period 1. Exclusion criteria were updated to include human immunodeficiency virus (HIV) testing at screening and extended timeline for receipt of live vaccines to comply with abatacept product label on live vaccination. Toxicity management guides was updated to include infusion reaction guidance and the protocol introduction was updated to include results of in-vitro drug interactions.
    25 Jan 2017
    The design was updated from 12-weeks to 24-weeks in Period 1 and provided limit on the number of methotrexate (MTX) inadequate responders. Subject rescue criteria, discontinuation criteria along with primary, secondary and additional study endpoints were updated. Sample size increased from 300 to 500 subjects with approximately 200 sites. Period 2 was extended up to 5 years. Other text was updated to provide clarity and improve readability.
    28 Mar 2017
    Permitted the addition or increase in doses of up to 2 conventional synthetic disease-modifying antirheumatic drugs (csDMARDs; except the combination of MTX and leflunomide) after Week 12 for those not achieving 20% improvement in both tender and swollen join counts. Added the additional endpoint of cumulative corticosteroid exposure at 24-weeks.
    12 Oct 2017
    Changes consistent with Amendment 3.01 for VHP countries. In addition, it allowed (at the discretion of the investigator) laboratory abnormalities to be recorded as AEs. Also this amendment replaced the dose of upadacitinib being studied for the primary analysis. The current dose of upadacitinib 30 mg QD was amended to 15 mg QD for patients not yet enrolled.
    12 Mar 2020
    (continued) The study drug accountability requirements were updated according to the revised sponsor guidelines. Text was added in Adverse Events of Special Interest to clarify that all cardiac, embolic, and thrombotic events will be adjudicated. In Toxicity Management herpes zoster and a recommendation for skin examination were added, the aspartate aminotransferase (AST) or alanine aminotransferase (ALT) parameters for management were updated, and study drug interruption prior to elective surgery in Period 2 was updated to 1 week.”
    12 Mar 2020
    Included an update to clarify guidance for the use of live vaccine administration during Period 2 such that if a live vaccine must be administered during study participation, study drug must be held for at least 30 days prior to the vaccination and at least 30 days after the vaccination (or longer if required locally). The removal of male contraception requirements for upadacitinib were clarified, as based on the calculated safety margins for human fetal exposure with seminal fluid transfer, risks to a fetus from a male taking the study drug are not anticipated. References to pregnancy of partners of male subjects were removed for consistency with the removal of male contraception requirements. Clarified permitted changes in background therapy and clarified background medication(s) optimization criteria in Period 2. Clarified concurrent use of JAK inhibitors is prohibited during the study. Added excluded biologic therapies to be consistent with current available biologic therapies in rheumatoid arthritis. Added allowance of high potency opiates for analgesic care related to AEs or SAEs. Provided guidance for interpretation of positive TB testing results in low risk subjects and added the ability to retest locally to confirm central laboratory result as a false-positive result is more likely in low risk subjects. Added use of Interferon Gamma Release Assay as a substitute for local TB testing since it is an equivalent assay to the QuantiFERON-TB Gold Plus. Specified that only subjects with newly identified TB risks are subject to chest x-rays to limit unnecessary procedures. Added discontinuation criteria concerning VTE. Included update that the DMC concluded its oversight of the study after the end of Period 1.
    04 Dec 2020
    Included changes in response to COVID-19 (or any state of emergency). An evaluation of the benefit and risk to subjects participating in the study relative to COVID-19 was added. Provisions for virtual or alternative locations for study visits due to the pandemic or any state of emergency were added. Clarifications were added regarding study activities that can be performed by phone/video conference or at local clinic/hospital/laboratory or through the optional home healthcare service in the event study visits are impacted by any state of emergency or pandemic situation. Study Procedures, including questionnaires, TB testing, chest X-rays, ECG, physical exam, efficacy assessments, laboratory tests, and pregnancy tests were updated to include provisions if an onsite visit cannot be performed due to the pandemic. Discontinuation criteria were revised regarding GI perforation and mitigation strategies related to the pandemic. Provision of study drug through direct-to-patient shipment was added. Language was added to include provision for modifications due to protocol deviations that may be due to the pandemic. Provisions allowing verbal consent in addition to the study informed consent in accordance with local regulations were added. Supplemental COVID-19 case report forms were added. Text was added to define pregnancy and product complaint reporting timeline as 24 hours from site staff awareness. Guidance was added for investigators on the management of subjects with suspected or confirmed COVID-19 infection. A clarification was added that the Investigator should also contact the AbbVie TA MD for confirmed ALT or AST > 8 x ULN in addition to immediate study drug interruption. The list of examples of commonly used strong cytochrome 3A inducers and the list of the adverse events of special interest was updated. Added language that remote monitoring may be employed as needed, due to COVID-19 or any pandemic/state of emergency. Updated the Ethical Conduct of the Study Se

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 04:31:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA